# Pfizer Inc. – Consensus ‘buy’ rating and 5.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.consensus-buy-rating-and-5.8-upside-potential/4121166217
- Published: 2024-07-26T12:02:52+01:00
- Author: Charlotte Edwards

**Pfizer Inc.** which can be found using ticker (PFE) now have 22 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The range
between the high target price and low target price is between $45.00 and $27.00 
calculating the mean target price we have $31.73. Now with the previous closing 
price of $29.98 and the analysts are correct then we can expect a percentage increase
in value of 5.8%. It’s also worth noting that there is a 50 day moving average of
$28.54 and the 200 day MA is $28.42. The market cap for the company is 171.02B. 
The stock price is currently at: $30.18 USD

 The potential market cap would be $181,000,386,914 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $9.72 and
a 0.93% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on: